时隔一年,曾击败全球“药王”K药的康方生物再次经历股价剧烈波动。4月底,康方宣布核心双抗产品依沃西在“头对头”临床试验中战胜百济神州的产品,同时PD-1单抗在美国获批两个适应症,依沃西国内第二个适应症也获批准。利好消息推动康方股价创下历史新高,创始人夏瑜表示,经过5年波折,股价从发行价涨至超100港元。然而,戏剧性的一幕随即发生,持有依沃西海外权益的Summit公司股价暴跌36%,导致康方股价一度...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.